Opendata, web and dolomites

ELDICO ED SIGNED

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ELDICO ED project word cloud

Explore the words cloud of the ELDICO ED project. It provides you a very rough idea of what is the project "ELDICO ED" about.

compounds    forecast    pending    consuming    time    segment    3m    10    industry    employees    atomic    approval    pharmaceutical    eldico    institutes    regime    m2    ed    crystallographers    patenting    designed    structure    2022    diffractometer    roi    limitations    18bn    diffraction    instruments    25    measured    commercial    saving    compound    opening    marketing    generating    particles    characterisation    substances    impossible    revenues    quality    structural    annum    minimum    unmeasurable    incorporating    agrochemicals    limited    3d    conventional    2024    overcomes    micro    size    shortening    mu    libraries    entering    hitherto    screened    500k    perform    exclusively    lower    crystal    crystalline    overcoming    drugs    electron    84    investigations    pharma    15    scientific    nanomaterials    unlocking    90    ray    first    pure    nano    solid    company    patent    sub    faster    market    310m    drug    11    discovery    techniques    issue    technique    sectors   

Project "ELDICO ED" data sheet

The following table provides information about the project.

Coordinator
ELDICO SCIENTIFIC AG 

Organization address
address: PARK INNOVAARE DELIVERY LAB
city: VILLIGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELDICO SCIENTIFIC AG CH (VILLIGEN) coordinator 50˙000.00

Map

 Project objective

Crystal structure determination is still a key issue in pharmaceutical industry. Any compound requires its 3D atomic structure to become “fully characterized” for patenting and marketing approval. However, only the structure of the 10% of all crystalline substances can be determine. The reason: Conventional X-ray diffraction methods are limited because they require crystal of a minimum size of 10 x 10 μm2 and high quality to be measured, which are often time consuming or even impossible to produce. For example in drug discovery the 90% of known, but not fully characterized crystalline compounds, could be rapidly screened for their scientific or commercial potential. Although electron diffraction technique overcomes the limitations of current techniques and allows investigations on nano-crystalline systems, currently there are no commercial instruments dedicated exclusively to electron diffraction. With ELDICO ED we bring to the market the first equipment (patent pending) designed to perform electron diffraction. We offer an electron diffractometer for the analysis of solid compounds enabling crystallographers entering the sub-µm regime for structural analysis of hitherto unmeasurable nano-crystalline particles. That way, they produce important structural information faster, with better quality and at lower cost, overcoming the limitations of X-ray analysis. We are opening up a new market segment: Pure Electron Diffraction. Our technology will impact the pharma sector by unlocking the characterisation of the 500k existing potential new drugs in their libraries, shortening time-to-market by 10%, saving €9-18bn per annum for testing and increasing revenues of up to €310M per annum for every new drug that comes to the market. Similar impact in key sectors like research institutes, agrochemicals and Advanced Nanomaterials is expected. With ELDICO ED we forecast generating revenues of €25.3M (ROI: 11.84) and incorporating 15 employees to our company during 2022-2024

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ELDICO ED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ELDICO ED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More